ALS prevalence in France

Approximately 8,000 people in France live with Charcot's disease, also known as amyotrophic lateral sclerosis (ALS), a rare neurodegenerative condition that progressively affects motor neurons in the brain and spinal cord. Patients gradually lose muscle function, leading to paralysis, and therapeutic solutions remain limited.

Innovative exoskeleton research

Pierre-François Pradat and his team at the Biomedical Imaging Laboratory in Paris are exploring new care approaches using Atalante X, a rehabilitation exoskeleton developed by Wandercraft. The device, designed and manufactured entirely in France, allows patients with varying degrees of gait disorders to stand, move, and exercise without using their hands, offering a level of mobility typically associated with a wheelchair.

Exoskeleton's technological features

Atalante X is described as a technological achievement, with the robotic structure capable of stabilizing itself autonomously to ensure safe movement for users. The exoskeleton is equipped with different walking modes, allowing for both stable, less physiological steps to build confidence and a more realistic walk that mimics natural, non-pathological movements.

Clinical trial details

The device was tested on about ten patients with ALS over four and a half months. Evaluations focused on various aspects of their condition, including muscle strength, walking ability, balance, postural control, pulmonary capacity, spasticity, and psychological factors such as pain, fatigue, anxiety, depression, and quality of life.

Initial findings and limitations

The first clinical benefits observed are encouraging, with the progression of symptoms and the disease appearing to slow during the training phase. These effects seem to persist in part after the stop of the exoskeleton's use. However, the small number of participants and the heterogeneity of their symptoms mean the results are not statistically significant.

Scientific contributions and future research

The study, which resulted in several scientific publications, allowed researchers to identify quantitative and reliable clinical markers of disease progression, a first in the literature. The next step for the researchers is to find the mechanisms that explain these improvements, whether they are related to muscular progress, better nerve-muscle transmission, or improved plasticity at the spinal cord or brain level. Many questions remain unresolved.